| Literature DB >> 29207600 |
Xinwei An1, Yuhan Hao2,3, Patricio I Meneses1.
Abstract
Human papillomavirus type 16 minor capsid protein L2 has been shown to assist in the initial entry and intracellular trafficking events leading to nuclear translocation of the viral genome. During our investigations of L2 function, we observed that expression of L2 in a keratinocyte cell line (HaCaT) resulted in phenotypic changes. In this manuscript, we present data that expression of the L2 protein in this cellular model system HaCaTs resulted in a shift from G0/G1 phase to mitotic S phase, as well as a reduced amount of retinoblastoma protein (Rb) and an increase in Cdc2 phosphorylation. We performed genome-wide host cell mRNA sequencing and identified 2586 differentially expressed genes upon HPV16 L2 expression. Via machine learning and protein network analysis, genes involved in cellular differentiation and proliferation were highlighted as impacted by L2. Our results have implications for the role of L2 at the viral production stages when the virus needs to prevent cellular differentiation while maintaining the cells ability to replicate DNA. Our study suggests a potential novel function of the L2 protein, as a regulator of cellular gene transcription.Entities:
Keywords: HPV16 L2; Pathology Section; RNA sequencing; Rb & Cdc2; cell cycle; transcriptome modification
Year: 2017 PMID: 29207600 PMCID: PMC5710881 DOI: 10.18632/oncotarget.21817
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1HPV16 L2 expression drives HaCaTs to S phase and affects Rb and Cdc2 expression and phosphorylation
Cells were transfected with 500ng p16L2h or empty vector pA3M. 18h after transfection, cells were collected and stained with Propidium Iodide (PI). DNA contents were measured with Accuri® C6 flow cytometer. A. Representative results of DNA content detection after empty vector pA3M or p16L2h plasmid transfection. B. Average percentage of the cell population in each cell cycle phase. Data are represented as mean±STD from four independent experiments. Significances of difference were analyzed with student’s t-test. *: G1: p = 0.0189; S: p = 0.0268. C. Representative Western Blotting of 500ng plasmid transfection. Average relative fold numbers shown above. Experiments were repeated three times. pRb and pCdc2 indicate phosphorylated Rb and Cdc2, respectively. Protein levels were first normalized to internal control Actin and then calculated as the fold number of pA3M transfected ones. D. Two-step real-time RT-PCR of Rb and Cdc2 mRNA levels. Depicted are Ct (Cycle number of threshold) values. Results were compared to the empty vector pA3M transfected group. Data are represented as mean±STD from three independent experiments. Black bars: pA3M transfected cells; gray bars: p16L2h transfected cells. *: p = 0.012; student’s t-test.
Comparison of cell counts among transfection conditions in DNA content detection.
| Total | G1 | S | G2/M | |
|---|---|---|---|---|
| pA3M | 55920 | 35425 | 7644 | 12624 |
| p16L2h | 30048 | 17024 | 5668 | 7418 |
| 0.00103 | 0.000536 | 0.037238 | 0.02458 |
Figure 2Expression of HPV16 L2 leads to up-regulation of 299 genes and down-regulation of 172 genes
HaCaT cells were transfected with 500ng p16L2h plasmid, and total RNAs were collected 18h after transfection. pA3M, p8fwb, p16L1h transfection, as well as untreated HaCaT cell RNAs, were used as the control. A. Schematic workflow of RNA-seq and sample preparation. B. A table of plasmids used in transfections for RNA-seq sample preparation. C. Principle Component Analysis (PCA) result with replicates from each group. D. Heatmap of top1000 most abundant variant transcripts among each replicates. E. and F. Venn diagram showing significantly regulated genes in different comparison conditions. Area enclosed by red lines indicates uniquely affected genes. E: Positively regulated genes in p16L2h transfection; F: Negatively regulated genes in p16L2h transfection; G: Volcano plot of differentially expressed genes (DEGs) in 16L2h:8fwb contrast. Vertical lines denote fold changes greater than ± 2-fold. Horizontal line denotes p-value > 0.001. Blue dots indicate genes down-regulated in p16L2h transfected group, and red dots indicate genes up-regulated.
Figure 3Cell proliferation and apoptosis related gene sets response to 16L2 expression
Enrichment plots for four selected gene sets are shown as above. Gene sets are selected based on their biological functions, GSEA p-values, and FDR q-values (p < 0.05, and FDR<0.1). Green line indicates accumulative enrichment score; black lines show ranking location of genes with gene set; gray color visualizes ranking metric scores; red and blue gradient colors suggest a positive or a negative regulation, respectively; and hits on the left side of orange dash lines are considered within leading edge subset (labeled LEA).
Figure 4Leading Edge Analysis (LEA) reveals core genes that account for the gene set’s enrichment signal, as well as genes that are overlapped among gene sets
A. Table of detailed GSEA results of enriched gene set “Positive Regulation of Cell Proliferation”. ES: Enrichment Score. B. Heatmap of clustered genes in the leading edge subsets of gene sets related to apoptosis and programmed cell death. Red and blue colors indicate positively and negatively regulated transcripts, respectively, upon HPV16 L2 protein expression. Darker the color, greater the fold difference. Rows are genes in leading edge subsets; columns are gene sets, which are labeled as 1 to 3. C. Table of explanations for Arabic numbers used in B.
Top IPA results for the 471 differential expressed genes (DEGs) identified from the 16L2h:8fwb contrast.
| Top Canonical Pathways | Overlap* | |
|---|---|---|
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 3.26E-14 | 11.3%, 34/300 |
| HMGB1 Signaling | 3.15E-11 | 15.3%, 20/131 |
| Hepatic Cholestasis | 8.73E-10 | 12.7%, 20/157 |
| Role of Osteoblasts, Osteoclasts and chondrocytes in Rheumatoid Arthritis | 8.80E-10 | 10.6%, 24/227 |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 1.87E-09 | 11.6%, 21/181 |
| TNF | 4.29E-20 | Activated |
| IL1A | 8.23E-14 | Activated |
| RELA | 1.73E-12 | Activated |
| Jnk (MAPK8) | 1.60E-10 | Activated |
| Cancer | 9.76E-04 - 4.36E-13 | 428 |
| Organismal Injury and Abnormalities | 9.78E-04 - 4.36E-13 | 434 |
| Dermatological Diseases and Conditions | 5.80E-04 - 1.95E-12 | 267 |
| Reproductive System Disease | 9.69E-04 - 1.55E-10 | 262 |
| Inflammatory Disease | 9.31E-04 - 1.09E-09 | 105 |
| Cell-To-Cell Signaling and Interaction | 9.76E-04 - 1.83E-12 | 89 |
| Cellular Development | 9.76E-04 - 4.45E-12 | 134 |
| Cellular Movement | 8.70E-04 - 1.26E-11 | 96 |
| Cellular Growth and Proliferation | 9.76E-04 - 3.74E-11 | 148 |
| Lipid Metabolism | 8.38E-04 - 1.53E-08 | 50 |
*Overlap: genes shared between 471 DEGs and genes in a canonical pathway
PANTHER identified genes altered by L2.
| GOs | Mapped Gene IDs |
|---|---|
| Biological Regulation (GO:0065007) | NGFR, SERPINB3, RAB26 |
| Cellular Component Organization or Biogenesis (GO:0071840) | NGFR, SPTA1, RAB26, ACTBL2, SNX10 |
| Cellular Process (GO:0009987) | ACTBL2, SIRPB2, TTC9, SNX10, LCN2, KLHDC7B, LGALSL, SSC4D, CLR1, ABCA5, ABCA4, NGFR, FA2H, NEURL3, SPTA1, LCE5A, PTPLAD2, SIRPB2, ARL14, RAB26, FGF13, S100A7, CAMK4 |
| Developmental Process (GO:0032502) | ZNF608, NGFR, NEURL3, LCE5A, FGF13, CD274 |
| Immune System Process (GO:0002376) | OLR1, NGFR, HSPB3, S100A7, C3 |
| Localization (GO:0051179) | SSC4D, ABCA5, ABCA4, ARL14, RAB26, SLC7A11, ACTBL2, LCN2, PARD6B, SNX10 |
| Locomotion (GO:0040011) | NGFR, SEMA4A |
| Metabolic Process (GO:0008152) | SSC4D, APOLD1, DHRS9, ABCA5, FA2H, HSPB3, ABCA4, LCE5A, S100A7, CAMK4, PTPRG, ZFP57, TTC9, LCN2, KLHDC7B, C3 |
| Multicellular Organismal Process (GO:0032501) | NGFR, LCE5A, RAB26 |
| Reproduction (GO:0000003) | NEURL3 |
| Response to Stimulus (GO:0050896) | NGFR, SEMA4A, HSPB3, CAMK4 |
PANTHER results sub-categories.
| GOs | Mapped Gene IDs | |
|---|---|---|
| Cellular Process (GO:0009987) | Cell Communication (GO:0007154) | NGFR, PTPLAD2, RAB26, FGF13, CAMK4, PARD6B |
| Cell Cycle (GO:0007049) | FGF13, S100A7, ACTBL2, PARD6B | |
| Cell Proliferation (GO:0008283) | NGFR | |
| Cellular Component Movement (GO:0006928) | NGFR | |
| Cytokinesis (GO:0000910) | ACTBL2 | |
| Immune System Process (GO:0002376) | Immune Response (GO:0006955) | OLR1, NGFR, C3 |
| Macrophage Activation (GO:0042116) | S100A7 | |
Figure 5Using top 50 genes selected by Machine Learning, PANTHER identified GOs of cell cycle and cell proliferation affected by L2 expression
Top 50 genes of combined SVM and RF scores were used as input for PANTHER. Biological processes were analyzed. A. All affected GOs. Numbers in each scallop indicate the number of genes identified in the 50 genes list that are classified as members of the corresponding GO. Explored scallops representing cellular process and immune system process were further illustrated in B. and C. B: GOs categorized as part of the cellular process. C: GOs categorized as part of the immune system process.